Abstract
The childhood interstitial lung diseases (chILD) Turkey registry (chILD-TR) was established in November 2021 to increase awareness of disease, and in collaboration with the centers to improve the diagnostic and treatment standards. Here, the first results of the chILD registry system were presented. In this prospective cohort study, data were collected using a data‐entry software system. The demographic characteristics, clinical, laboratory, radiologic findings, diagnoses, and treatment characteristics of the patients were evaluated. Clinical characteristics were compared between two main chILD groups ((A) diffuse parenchymal lung diseases (DPLD) disorders manifesting primarily in infancy [group1] and (B) DPLD disorders occurring at all ages [group 2]). There were 416 patients registered from 19 centers. Forty-six patients were excluded due to missing information. The median age of diagnosis of the patients was 6.05 (1.3–11.6) years. Across the study population (n = 370), 81 (21.8%) were in group 1, and 289 (78.1%) were in group 2. The median weight z-score was significantly lower in group 1 (− 2.0 [− 3.36 to − 0.81]) than in group 2 (− 0.80 [− 1.7 to 0.20]) (p < 0.001). When we compared the groups according to chest CT findings, ground-glass opacities were significantly more common in group 1, and nodular opacities, bronchiectasis, mosaic perfusion, and mediastinal lymphadenopathy were significantly more common in group 2. Out of the overall study population, 67.8% were undergoing some form of treatment. The use of oral steroids was significantly higher in group 2 than in group 1 (40.6% vs. 23.3%, respectively; p = 0.040).
Conclusion: This study showed that national registry allowed to obtain information about the frequency, types, and treatment methods of chILD in Turkey and helped to see the difficulties in the diagnosis and management of these patients.
What is Known: • Childhood interstitial lung diseases comprise many diverse entities which are challenging to diagnose and manage. | |
What is New: • This study showed that national registry allowed to obtain information about the frequency, types and treatment methods of chILD in Turkey and helped to see the difficulties in the diagnosis and management of these patients. Also, our findings reveal that nutrition should be considered in all patients with chILD, especially in A-DPLD disorders manifesting primarily in infancy. |
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Abbreviations
- BAL:
-
Bronchoalveolar lavage
- ChILD:
-
Childhood interstitial lung diseases
- ChILD-TR:
-
ChILD registry system in Turkey
- CT:
-
Computed tomography
- DLCOadj:
-
Adjusted diffusion capacity for carbon monoxide
- DPLD:
-
Diffuse parenchymal lung disease
- GERD:
-
Gastroesophageal reflux disease
- FVC:
-
Forced vital capacity
- FEV1:
-
Forced expiratory volume in 1 s
- NEHI:
-
Neuroendocrine cell hyperplasia of infancy
- TLC:
-
Total lung capacity
- WLL:
-
Whole-lung lavage
References
Nayir Buyuksahin H, Kiper N (2023) Childhood interstitial lung disease. Pediatr Allergy Immunol Pulmonol 36:5–15
Griese M (2022) Etiologic classification of diffuse parenchymal (interstitial) lung diseases. J Clin Med 11
Cinel G, Kiper N, Orhan D, Emiralioglu N, Yalcin E, Dogru D, Ozcelik U, Oguz B, Haliloglu M (2020) Childhood diffuse parenchymal lung diseases: we need a new classification. Clin Respir J 14:102–108
Rice A, Tran-Dang MA, Bush A, Nicholson AG (2013) Diffuse lung disease in infancy and childhood: expanding the chILD classification. Histopathology 63:743–755
Kurland G, Deterding RR, Hagood JS, Young LR, Brody AS, Castile RG, Dell S, Fan LL, Hamvas A, Hilman BC, Langston C, Nogee LM, Redding GJ (2013) An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Respir Crit Care Med 188:376–394
Clement A, Nathan N, Epaud R, Fauroux B, Corvol H (2010) Interstitial lung diseases in children. Orphanet J Rare Dis 5:22
Ferraro VA, Zanconato S, Zamunaro A, Carraro S (2020) Children's interstitial and diffuse lung diseases (ChILD) in 2020. Children (Basel) 7
(2014) AHRQ Methods for Effective Health Care. In: Gliklich RE, Dreyer NA, Leavy MB (eds) Registries for evaluating patient outcomes: a user's guide. Agency for Healthcare Research and Quality (US), Rockville (MD)
Griese M, Seidl E, Hengst M, Reu S, Rock H, Anthony G, Kiper N et al (2018) International management platform for children’s interstitial lung disease (chILD-EU). Thorax 73:231–239
Bush A, Cunningham S, de Blic J, Barbato A, Clement A, Epaud R, Hengst M, Kiper N, Nicholson AG, Wetzke M, Snijders D, Schwerk N, Griese M (2015) European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax 70:1078–1084
Clement A, de Blic J, Epaud R, Galeron L, Nathan N, Hadchouel A, Barbato A, Snijders D, Kiper N, Cunningham S, Griese M, Bush A, Schwerk N (2016) Management of children with interstitial lung diseases: the difficult issue of acute exacerbations. Eur Respir J 48:1559–1563
Seidl E, Schwerk N, Carlens J, Wetzke M, Cunningham S, Emiralioğlu N, Kiper N, Lange J, Krenke K, Ullmann N, Krikovszky D, Maqhuzu P, Griese CA, Schwarzkopf L, Griese M (2022) Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe. Thorax 77:781–789
Griese M, Kappler M, Stehling F, Schulze J, Baden W, Koerner-Rettberg C, Carlens J, Prenzel F, Nährlich L, Thalmeier A, Sebah D, Kronfeld K, Rock H, Ruckes C, Wetzke M, Seidl E, Schwerk N (2022) Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease. Orphanet J Rare Dis 17:289
Casey AM, Deterding RR, Young LR, Fishman MP, Fiorino EK, Liptzin DR (2020) Overview of the ChILD Research Network: a roadmap for progress and success in defining rare diseases. Pediatr Pulmonol 55:1819–1827
McKnight L, Schultz A, Vidic N, Palmer EE, Jaffe A (2023) Learning to make a difference for chILD: value creation through network collaboration and team science. Pediatr Pulmonol
Nevel RJ, Deutsch GH, Craven D, Deterding R, Fishman MP, Wambach JA, Casey A et al (2023) The US national registry for childhood interstitial and diffuse lung disease: report of study design and initial enrollment cohort. Pediatr Pulmonol
Kiper N, Emiralioglu N. Nutrition booklet for families of patients with chILD. Available from: www.klinikum.uni-muenchen.de/Child-EU. [Last accessed: January 6, 2020]
Comes A, Wong AW, Fisher JH, Morisset J, Johannson KA, Farrand E, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Khalil N, Sadatsafavi M, Shapera S, To T, Wilcox PG, Collard HR, Ryerson CJ (2022) Association of BMI and change in weight with mortality in patients with fibrotic interstitial lung disease. Chest 161:1320–1329
Rinaldi S, Gilliland J, O’Connor C, Seabrook JA, Mura M, Madill J (2021) Fat-free mass index controlled for age and sex and malnutrition are predictors of survival in interstitial lung disease. Respiration 100:379–386
Gilbert C, Bush A, Cunningham S (2015) Childhood interstitial lung disease: family experiences. Pediatr Pulmonol 50:1301–1303
Stubbs KH, McMahon MXH, Popler J, Berry RC, Sharp WG (2022) Multidisciplinary feeding treatment for a patient with interstitial lung disease. Pediatr Pulmonol 57:3183–3185
Ghisa M, Marinelli C, Savarino V, Savarino E (2019) Idiopathic pulmonary fibrosis and GERD: links and risks. Ther Clin Risk Manag 15:1081–1093
Dziekiewicz M, Marczak H, Banasiuk M, Aksionchyk M, Krenke K, Banaszkiewicz A (2023) Characteristics of gastroesophageal reflux disease in children with interstitial lung disease. Pediatr Pulmonol 58:171–177
Nathan N, Griese M, Michel K, Carlens J, Gilbert C, Emiralioglu N, Torrent-Vernetta A, Marczak H, Willemse B, Delestrain C, Epaud R (2023) Diagnostic workup of childhood interstitial lung disease. Eur Respir Rev 32
Griese M, Schwerk N, Carlens J, Wetzke M, Emiralioğlu N, Kiper N, Lange J, Krenke K, Seidl E (2023) Minimal important difference in childhood interstitial lung diseases. Thorax 78:476–483
Ring AM, Carlens J, Bush A, Castillo-Corullón S, Fasola S, Gaboli MP, Griese M, Koucky V, La Grutta S, Lombardi E, Proesmans M, Schwerk N, Snijders D, Nielsen KG, Buchvald F (2020) Pulmonary function testing in children's interstitial lung disease. Eur Respir Rev 29
Spagnolo P, Bush A (2016) Interstitial lung disease in children younger than 2 years. Pediatr 137
Verma N, Altmayer S, Hochhegger B, Barros MC, Rajderkar D, Mohammed TL (2021) ChILD: a pictorial review of pulmonary imaging findings in childhood interstitial lung diseases. Curr Probl Diagn Radiol 50:95–103
Liang TI, Lee EY (2020) Interstitial lung diseases in children, adolescents, and young adults: different from infants and older adults. Radiol Clin North Am 58:487–502
Nayir Buyuksahin H, Basaran O, Balık Z, Bilginer Y, Ozen S, Dogru D (2023) Interstitial lung disease in autoinflammatory disease in childhood: a systematic review of the literature. Pediatr Pulmonol 58:367–373
Doğru D, Yalçin E, Aslan AT, Ocal T, Ozçelik U, Güçer S, Kale G, Haliloglu M, Kiper N (2009) Successful unilateral partial lung lavage in a child with pulmonary alveolar proteinosis. J Clin Anesth 21:127–130
Emiralioglu N, Beken B, Ozcan HN, Yalcin E, Dogru D, Ozcelik U, Haliloglu M, Kiper N (2016) Diagnosis and treatment of pulmonary alveolar microlithiasis. Pediatr Int 58:805–807
Acknowledgements
We thank all the families and patients for their participation. We thank all the chILD-TR collaborators.
Funding
This project was funded by Hacettepe University Scientific Research Project Coordination Department (Project number: TOA-2021–19075).
Author information
Authors and Affiliations
Contributions
H.N.B., N.E., and N.K. wrote the main manuscript text. All authors contributed data and reviewed the manuscript.
Corresponding author
Ethics declarations
Ethics approval
The establishment of the national registry and data input was approved by the local ethics committee (Hacettepe University Ethics Board, reference numbers: GO 20/604), in addition to the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Competing interests
The authors declare no competing interests.
Additional information
Communicated by Peter de Winter
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nayır-Büyükşahin, H., Emiralioğlu, N., Kılınç, A.A. et al. Childhood interstitial lung disease in Turkey: first data from the national registry. Eur J Pediatr 183, 295–304 (2024). https://doi.org/10.1007/s00431-023-05290-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-023-05290-9